



Office of Technology Licensing

t 901.495.2342 f 901.495.3148

St. Jude Children's
Research Hospital

ALVAC - Danny Thomas, Founder

December 17, 2008

Commissioner for Patents
Mail Stop Amendment
PO Box 1450
Alexandria, VA 22313-1450

Re: Appl. No. 10/078,927; Filed: February 19, 2002
For: CYCLIN DEPENDENT KINASE 5 PHOSPHORYLATION
OF DISABLED 1 PROTEIN

Inventors: Curran, *et al*
Our Ref: SJ-01-0032

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. Notice to Comply with Requirements for Patent applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pgs);
2. Revised Sequence Listing (2 pgs); and
3. Copy of the Notice to Comply received from US PTO (1 pg).

No fee is believed to be required for consideration of the Amendment and Response to Final Office Action. If applicants are incorrect and a fee is required the Commissioner is hereby authorized to charge such fee to Deposit Account No. 501968.

Regards,

Shawn A. Hawkins

Shawn A. Hawkins
Reg. No. 50,318

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Curran; *et al.* : Art Unit: 1656
Serial No. 10/078,927 : Examiner: David J. Steadman
Filed: February 19, 2002 : Atty Docket: SJ-01-0032
For: Cyclin Dependent Kinase 5
Phosphorylation of Disabled 1
Protein

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURES**

Mail Stop Sequence
Commissioner for Patents
P.O. Box 22313 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply mailed December 2, 2008, setting a one (1) month statutory period for response, please enter the following sequence listing and remarks into the record:


Remarks

A substitute sequence listing that contains SEQ ID Nos. 1 -3 is submitted with this response. The paper copy of the sequence listing in this amendment is identical to the ASCII text copy of the sequence listing also filed with this amendment. The content of the present sequence listing does not contain new matter. Incorporation of the sequence listing into the specification is respectfully requested.

Conclusion

It is not believed that extensions of time or fees are required, beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 501968.

Respectfully submitted,



Shawn A. Hawkins
Registration No. 50,318

Notice to Comply	Application No. 10078927	Applicant(s) CURRAN ET AL.
	Examiner David J. Steadman	Art Unit 1656
<p>NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES</p> <p>Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).</p> <p>The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):</p> <ul style="list-style-type: none"> <input type="checkbox"/> 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). <input type="checkbox"/> 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). <input type="checkbox"/> 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). <input checked="" type="checkbox"/> 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." <input type="checkbox"/> 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). <input type="checkbox"/> 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). <input type="checkbox"/> 7. Other: <p>Applicant Must Provide:</p> <ul style="list-style-type: none"> <input checked="" type="checkbox"/> An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". <input checked="" type="checkbox"/> An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. <input checked="" type="checkbox"/> A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). <p>For questions regarding compliance to these requirements, please contact:</p> <p>For Rules Interpretation, call (571) 272-0731 or (571) 272-0951 For CRF Submission Help, call (571) 272-2510 PatentIn Software Program Support Technical Assistance 1-866-217-9197 or 703-305-3028 or 571-272-6845 PatentIn Software is Available At www.USPTO.gov</p> <p>PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY</p>		
/David J. Steadman/ Primary Examiner, Art Unit 1656		